Scott Chasan-Taber
Overview
Explore the profile of Scott Chasan-Taber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson S, Louie T, Gerding D, Cornely O, Chasan-Taber S, Fitts D, et al.
Clin Infect Dis
. 2014 May;
59(3):345-54.
PMID: 24799326
Background: Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational...
2.
McGowan M, Tardif J, Ceska R, Burgess L, Soran H, Gouni-Berthold I, et al.
PLoS One
. 2012 Nov;
7(11):e49006.
PMID: 23152839
Objectives: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy...
3.
Raal F, Santos R, Blom D, Marais A, Charng M, Cromwell W, et al.
Lancet
. 2010 Mar;
375(9719):998-1006.
PMID: 20227758
Background: Homozygous familial hypercholesterolaemia is a rare genetic disorder in which both LDL-receptor alleles are defective, resulting in very high concentrations of LDL cholesterol in plasma and premature coronary artery...
4.
Fishbane S, Delmez J, Suki W, Hariachar S, Heaton J, Chasan-Taber S, et al.
Am J Kidney Dis
. 2010 Jan;
55(2):307-15.
PMID: 20042256
Background: Sevelamer carbonate powder for oral suspension is a new dosage form of sevelamer, which may be suited to once-daily dosing. Study Design: Randomized parallel open-label study. Setting & Participants:...
5.
Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf J, Ortiz A, et al.
Nephrol Dial Transplant
. 2008 Sep;
24(1):278-85.
PMID: 18820280
Background: Inadequate phosphorus control is associated with increased morbidity and mortality in patients with CKD stage 5. Although phosphate binders are often used in patients on peritoneal dialysis (PD), no...
6.
Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, et al.
Clin J Am Soc Nephrol
. 2008 May;
3(4):1125-30.
PMID: 18450923
Background And Objectives: Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. This study investigated the ability...
7.
Louie T, Peppe J, Watt C, Johnson D, Mohammed R, Dow G, et al.
Clin Infect Dis
. 2006 Jul;
43(4):411-20.
PMID: 16838228
Background: Current antibiotic therapies for Clostridium difficile-associated diarrhea have limitations, including progression to severe disease, recurrent C. difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic...
8.
Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow G, Raggi P
Am Heart J
. 2005 May;
149(5):820-5.
PMID: 15894962
Background: Patients affected by end-stage renal disease (ESRD) demonstrate a very high cardiovascular risk mediated by traditional cardiovascular risk factors as well as abnormal mineral metabolism and a state of...
9.
Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis
Raggi P, James G, Burke S, Bommer J, Chasan-Taber S, Holzer H, et al.
J Bone Miner Res
. 2005 Apr;
20(5):764-72.
PMID: 15824849
Unlabelled: We performed a post hoc analysis of a 52-week randomized trial conducted in adult hemodialysis patients that compared the effects of calcium-based phosphate binders and sevelamer, a nonabsorbable polymer,...
10.
Garg J, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, et al.
Arthritis Rheum
. 2005 Jan;
52(1):290-5.
PMID: 15641045
Objective: Gout affects a large fraction of persons with advanced chronic kidney disease, and hyperuricemia may increase the risk of cardiovascular disease. Several hypouricemic agents are contraindicated in patients with...